Search

Objective: Pathological angiogenesis is a hallmark of various diseases characterized by local hypoxia and inflammation. These disorders can be treated with inhibitors of angiogenesis, but current compounds display a variety of side effects and lose efficacy over time. This makes the identification of novel signaling pathways and pharmacological targets involved in angiogenesis a top priority. Approach and Results: Here, we show that inactivation of FAAH (fatty acid amide hydrolase), the enzyme responsible for degradation of the endocannabinoid anandamide, strongly impairs angiogenesis in vitro and in vivo. Both, the pharmacological FAAH inhibitor URB597 and anandamide induce downregulation of gene sets for cell cycle progression and DNA replication in endothelial cells. This is underscored by cell biological experiments, in which both compounds inhibit proliferation and migration and evoke cell cycle exit of endothelial cells. This prominent antiangiogenic effect is also of pathophysiological relevance in vivo, as laser-induced choroidal neovascularization in the eye of FAAH -/- mice is strongly reduced., Conclusions: Thus, elevation of endogenous anandamide levels by FAAH inhibition represents a novel antiangiogenic mechanism.

Chitin-binding domain (ChBD) of chitinase A1 from Bacillus circulans WL-12 comprises 45 amino acids and exhibits remarkably high specificity to chitin (Hashimoto, M., Ikegami, T., Seino, S., Ohuchi, N., Fukada, H., Sugiyama, J., Shirakawa, M., Watanabe, T., 2000. Expression and characterization of the chitin-binding domain of chintinase A1 from B. circulans WL-12. J. Bacteriol. 182, 3045-3054.). To investigate the feasibility of exploiting ChBD as affinity tags to confine enzymes of interest on chitin, ChBD fused to the C-terminus of the gene encoding D-hydantoinase was constructed. Subsequent expression of the hybrid protein in Escherichia coli gave a soluble fraction accounting for 8% of total cell protein content. Direct adsorption of the ChBD-fused D-hydantoinase on chitin beads was carried out, and SDS-PAGE analysis showed that the linkage between the fusion protein and the affinity matrix was highly specific, substantially stable, and reversible. As compared to its free counterpart, the immobilized D-hydantoinase exhibited higher tolerance to heat and gained a half life of 270 h at 45 degrees C. In addition, the shelf life (defined as 50% of initial activity remained) of the immobilized enzyme stored at 4 degrees C was found to reach 65 days. Furthermore, D-hydantoinase immobilized on chitin could be reused for 15 times to achieve the conversion yield exceeding 90%. Overall, it illustrates the great usefulness of ChBD for enzyme immobilization.

The endocannabinoid 2-arachidonoylglycerol (2-Delta(4)Ach-Gro) activates human platelets in platelet-rich plasma at physiological concentrations. The activation was inhibited by selective antagonists of CB(1) and CB(2) cannabinoid receptors, but not by acetylsalicylic acid. Human platelets can metabolize 2-Delta(4)Ach-Gro by internalization through a high affinity transporter (K(m) = 300 +/- 30 nM, V(max) = 10 +/- 1 pmol.min(-1).mg protein(-1)), followed by hydrolysis by a fatty acid amide hydrolase (K(m) = 8 +/- 1 microM, V(max) = 400 +/- 50 pmol.min(-1).mg protein(-1)). The anandamide transport inhibitor AM404, and anandamide itself, were ineffective on 2-Delta(4)Ach-Gro uptake by platelets, whereas anandamide competitively inhibited 2-Delta(4)Ach-Gro hydrolysis (inhibition constant = 10 +/- 1 microM). Platelet activation by 2-Delta(4)Ach-Gro was paralleled by an increase of intracellular calcium and inositol-1,4,5-trisphosphate, and by a decrease of cyclic AMP. Moreover, treatment of preloaded platelet-rich plasma with 2-Delta(4)Ach-Gro induced an approximately threefold increase in [(3)H]2-Delta(4)Ach-Gro release, according to a CB receptor-dependent mechanism. On the other hand, ADP and collagen counteracted the activation of platelets by 2-Delta(4)Ach-Gro, whereas 5-hydroxytryptamine (serotonin) enhanced and extended its effects. Remarkably, ADP and collagen also reduced [(3)H]2-Delta(4)Ach-Gro release from 2-Delta(4)Ach-Gro-activated platelets, whereas 5-hydroxytryptamine further increased it. These findings suggest a so far unnoticed interplay between the peripheral endocannabinoid system and physiological platelet agonists.